Antibody-drug conjugates on the march

One of AstraZeneca’s most decisive moves last year came in March, when it signed a multi-billion dollar deal with Japan’s Daiichi Sankyo, focused on just one breast cancer drug. But with the drug, Enhertu, now approved in the US, doctors could have a powerful new medicine in their arsenal against breast cancer. Richard Staines spoke with Gilles Gallant, Daiichi’s oncology R&D team leader about the future plans for the drug, and the antibody-drug conjugate technology behind it.